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Abstract 
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human 
malignancies. Dissecting the mechanisms underlying PDA development is 
important for developing early detection methods and effective preventions and 
therapies for the disease. PDA is considered to arise from distinct precursor 
lesions, including pancreatic intraepithelial neoplasia (PanIN) and intraductal 
papillary mucinous neoplasia (IPMN). However, little is known about molecular 
mechanisms of development of IPMN and IPMN-derived PDA. We have recently 
reported that loss of Brg1, a core subunit of SWI/SNF chromatin remodeling 
complexes, cooperates with oncogenic Kras to form cystic neoplastic lesions 
that resemble human IPMN and progress to PDA. Brg1 null IPMN-PDA is less 
lethal compared to PanIN-derived PDA (PanIN-PDA) driven by mutant Kras and 
hemizygous p53 deletion, mirroring prognostic trends in PDA patients. Brg1 null 
IPMN-PDA possesses a distinct molecular signature that supports less 
malignant potential compared to PanIN-PDA. Furthermore, Brg1 deletion inhibits 
Kras-dependent PanIN development from adult acinar cells, but promotes 
Kras-driven preneoplastic transformation in adult duct cells. Therefore, Brg1 is a 
determinant of context-dependent Kras-driven pancreatic tumorigenesis and 
chromatin remodeling may underlie the development of distinct PDA subsets. 
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Understanding molecular mechanism of IPMN and IPMN-derived PDA could 




PDA is one of the most devastating and lethal cancers with less than five 
percent of patients surviving five years after diagnosis, and the incidence of this 
disease is increasing. Therefore, understanding the pathogenesis of PDA is 
important for developing early detection methods and effective preventions and 
therapies for the disease. PDA is assumed to arise from three morphologically 
different precursor lesions: pancreatic intraepithelial neoplasias (PanINs; the 
most common precursor lesions in humans), intraductal papillary mucinous 
neoplasias (IPMNs), or mucinous cystic neoplasias (MCNs). Because 
IPMN-derived PDA (IPMN-PDA) has a more favorable prognosis for survival 
compared to PanIN-derived PDA (PanIN-PDA)1-3, it has been considered that 
IPMN-PDA is biologically distinct 4. However, to date, very few studies have 
addressed molecular characteristics and mechanisms underlying the 
development of IPMN and IPMN-PDA. It has recently been shown that the 
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mutations of Kras and GNAS are observed in cystic fluid of IPMNs 5 and 
resected IPMNs 6, and the detection of GNAS mutation is specific to distinguish 
IPMNs from other cystic neoplasms 5. In addition, RNF43 has recently been 
reported to be mutated in both IPMNs and MCNs 5, although the functional roles 
of GNAS and RNF43 in the development of IPMNs are still unknown.  
There is growing evidence to support a role for epigenetic regulators in the 
development and progression of cancer 7. Chromatin remodelers are a group of 
epigenetic regulators that utilize ATP hydrolysis to disrupt DNA-protein contacts 
in order to regulate gene expression 8. Inactivating mutations or loss of 
expression of several subunits of multi-protein chromatin-remodeling SWI/SNF 
complexes have recently been identified in various human cancers 9-13, including 
PDA 14. For PDA, mutations in Brg1 (SMARCA4 in human), a catalytic ATPase 
subunits of the SWI/SNF complex, and other subunits of the complex are 
identified in over 30% of human PDA cases 15, 16. Of note, Brg1 expression was 
reported to be frequently reduced or lost in human IPMN samples 17. However, it 
remained unclear whether Brg1 plays a functional role in the specification of 
PDA precursors and PDA development.  
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Genetically engineered mouse models provide valuable insights into the 
pathogenesis of diseases and allow the testing of the hypothesis that particular 
genes are involved in pathogenesis. We have recently generated transgenic 
mice in which Brg1 is deleted in the context of oncogenic Kras (KrasG12D) in the 
pancreas under the control of endogenous Ptf1a promoter (KP.Brg1 mice) 18. 
KP.Brg1 mice results in spontaneous development of cystic neoplasms which 
resembles human branch-duct IPMNs. Furthermore, the IPMN lesions progress 
to form IPMN-derived PDA, which carry a better prognosis than PanIN-PDA. In 
this article, we discuss the molecular mechanism and characteristics of IPMN 
and IPMN-derived PDA in the aspect of the role of chromatin regulator, Brg1, 
and their cellular origin.  
 
Pancreatic loss of Brg1 in the context of oncogneic Kras results in 
formation of cystic neoplasms that resemble human IPMNs. 
Brg1 was expressed in all pancreatic cell types in mice18. Mutant Kras 
(KrasG12D) is sufficient to drive the development of PanIN and PDA when 
targeted to the developing mouse pancreas 19. To investigate whether Brg1 loss 
alters Kras-driven pancreatic transformation, we generated Ptf1a-Cre; KrasG12D; 
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Brg1f/f (KP.Brg1) mice. KP.Brg1 mice developed grape-like cystic structures 
throughout the pancreas (Fig. 1a,b)18. The epithelial-lined cystic lesions were 
Brg1-negative, CK19-positive, and alcian blue-positive indicative of 
mucin-production. Further examination revealed that (i) the pancreatic duct 
system had a direct functional connection to the multiple branch-duct dilated 
cystic structures without main-duct dilatation (Fig. 1a), (ii) the cystic lesions 
lacked ovarian-like stroma characterized by expression of ERα and PR. (iii) The 
cystic epithelium was Muc1+, Muc2-, Muc5+. Collectively, the neoplastic cystic 
lesions most closely resembled human branch-duct IPMNs of pancreatobiliary 
type.  
 
IPMN-like lesions progress to form IPMN-derived PDA 
IPMN lesions in KP.Brg1 mice contained varying grades of dysplasia. 
Furthermore, IPMN-derived PDA was formed in a subset of KP.Brg1 mice 
(hereafter referred to as IPMN-PDA mice) (Fig. 1c,d). Morphologically, 
IPMN-PDAs were indistinguishable from PanIN-derived PDAs in Ptf1a-Cre; 
KrasG12D; p53f/+ mice (hereafter referred to as PanIN-PDA mice) 20 .  
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Brg1 null IPMN-PDA is less lethal than PanIN-PDA and carries a distinct 
molecular signature 
Similar to the human situation2, 3, 21, IPMN-PDA mice carried a more 
favorable prognosis for survival compared to PanIN-PDA mice. Cell proliferation 
of IPMN-PDA was significantly lower than that of PanIN-PDA. After establishing 
cancer cell lines derived from PDA that formed in IPMN- and PanIN-PDA mice, 
subcutaneous transplantation experiments showed that IPMN-PDA cells are 
intrinsically less proliferative compared to PanIN-PDA cells. 
Deep sequencing analysis of RNA isolated from IPMN- and PanIN-PDA 
cells revealed that several genes previously shown to support malignancy 
(including Mmp7, Gabrp, Hmga2, Clic3, and Adamts1) in PDA were among the 
most down-regulated genes in IPMN-PDA compared to PanIN-PDA22-28. 
Additional pathway analysis revealed that IPMN-PDAs displayed a decreased 
gene expression signature for those signaling cascades regulating invasion and 
metastasis, supporting for the notion that IPMN-PDA possesses less malignant 
potential compared to PanIN-PDA. Neither significant changes in expression of 
GNAS and RNF43 nor SNPs/mutations in GNAS were detected when 
comparing IPMN- vs. PanIN-PDA. 
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Brg1 blocks IPMN formation from adult pancreatic duct cells but is critical 
for acinar-derived PanIN formation 
The cellular origins of PDA have been extensively debated. Considerable 
functional evidence from mouse models suggests that cellular origin of PanINs is 
acinar cell29-32. Because IPMNs are located within and are continuous with the 
main and/or branch duct, they are thought to arise from duct cell compartments. 
However, cellular origin of IPMNs remained unclear. We next asked the question 
of whether the striking biological differences between PanIN-PDA and 
IPMN-PDA might reflect a difference in the cellular origin of the cancer precursor 
lesions. We generated transgenic mice permitting expression of mutant Kras 
and Brg1 deletion specifically in adult acinar cells upon tamoxifen treatment 30, 33, 
and could not detect any IPMN lesions. Moreover, the number of PanINs was 
significantly reduced in the absence of Brg1 in adult acinar cells. Of note, the 
majority of the few PanINs developing in the mice retained Brg1 expression, 
indicating that Brg1 plays a critical role in acinar-derived PanIN formation. Next 
we examined whether IPMN lesions can originate from adult pancreatic duct 
cells by using the tamoxifen inducible Hnf1b-CreERT2 line that permits Cre 
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recombination in adult duct cells 34. Notably, a subset of Hnf1b-CreERT2; 
KrasG12D; Brg1f/f mice showed the formation of a mucinous dilated duct structure 
reminiscent of the IPMN lesions. Therefore, Brg1 modulates cell-type specific 
responses to oncogenic Kras, representing a critical node for acinar to PanIN 
transformation, but an inhibitor of duct cell -derived neoplasia. 
 
Conclusion and future direction 
In summary, the chromatin regulator Brg1 inhibits formation of IPMN and 
IPMN-derived PDA in the context of oncogenic Kras. Brg1 blocks IPMN 
formation from adult pancreatic duct cells but is critical for acinar-derived PanIN 
formation. Although IPMN-PDA per se is histologically indistinguishable from 
PanIN-PDA, IPMN-PDA is biologically and molecularly distinct subtype with 
different cellular origin. KP.Brg1 mice are a valid mouse model for investigating 
mechanisms underlying development of IPMN and IPMN-derived PDA. Future 
studies are needed to clarify which Brg1-regulated epigenetic and genetic 
changes contribute to the cell-type specific effects, and how such differences 
determine the development and character of PDA arising from different 
precursor lesions with different biological behavior. An improved understanding 
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of molecular mechanism of IPMN and IPMN-derived PDA and their cellular 
origin could reveal new avenues for novel diagnostic and therapeutic strategies 
of the disease. 
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Figure Legends 
Figure 1  
Pancreatic loss of Brg1 in the context of oncogneic Kras results in 
formation of IPMNs and IPMN-derived pancreatic duct adenocarcinoma 
(a) Macroscopic view of a Ptf1a-Cre; KrasG12D; Brg1f/f pancreas at 9 weeks of 
age. The pancreas showed extensive grape-like cystic structures throughout the 
pancreas that resembles human branch-duct IPMNs. To prove a possible 
connection of the cystic neoplastic lesions to the pancreatic duct system blue 
dye (bromophenolblue) was injected in the common bile duct to allow retrograde 
filling of the duct system. (b) H&E staining of the IPMN-like lesions in Ptf1a-Cre; 
KrasG12D; Brg1f/f pancreas. (c,d) PDA was formed in Ptf1a-Cre; KrasG12D; Brg1f/f 
mice at 18 weeks of age. (c) Microscopic (H&E) view (arrowheads; PDA, arrow; 
adjacent IPMN cystic lesion). (d) Ki67/CK19/DAPI costaining of the 
IPMN-derived PDA in Ptf1a-Cre; KrasG12D; Brg1f/f mice. 
 
Figure 2.  
A suggested mechanistic model of IPMN and IPMN-derived PDA 
  15 
The chromatin regulator Brg1 blocks IPMN formation from adult pancreatic duct 
cells in the context of oncogenic Kras, while Brg1 is critical for acinar cell-derived 
PanIN formation. 
 
Figure 1
Figure 2
